Development asset linked to Daihong Liu in public FDA and regional records.
pharma · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu
Daihong Liu drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 8
- Patents
- 0
Daihong Liu pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Daihong Liu drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Daihong Liu in public FDA and regional records.
-
Development asset linked to Daihong Liu in public FDA and regional records.
-
Development asset linked to Daihong Liu in public FDA and regional records.
-
Development asset linked to Daihong Liu in public FDA and regional records.
-
Development asset linked to Daihong Liu in public FDA and regional records.
-
Development asset linked to Daihong Liu in public FDA and regional records.